Replay
Back

Mark Blumenkranz

  • Professor

Mark Blumenkranz, MD, is a Co-founder of Replay’s product company utilizing HSV’s ability to deliver big DNA in the eye. Mark S. Blumenkranz, M.D., MMS, is the HJ Smead Professor Emeritus in the Department of Ophthalmology, Emeritus, at the Stanford School of Medicine. He received his Undergraduate, Master’s degree in Biochemical Pharmacology, and MD at Brown. He completed his surgical internship and ophthalmic residency training at Stanford Health Care and a fellowship in vitreoretinal diseases at the Bascom Palmer Eye Institute where he was appointed a member of the faculty following completion of his training in 1980. In 1985 he founded the Retinal Fellowship Training Program at the William Beaumont Eye Institute in Royal Oak Michigan, and served as the Fellowship Director until 1992. He returned to Stanford Medicine in 1992 as head of the vitreoretinal service and was appointed to serve as the Department Chairman in 1997. He served in that capacity until 2015. He completed the Stanford Executive Program at the Graduate School of Business in 2004 He played a leading role in the planning, fundraising and construction of the Byers Eye Institute at Stanford Medicine and served as founding Director from its opening in September 2010 through June 2015.

Dr. Blumenkranz has a longstanding interest and expertise in corporate technology. He was a director and principal trial designer at Oculex Pharmaceuticals for their successful phase 2 Ozurdex study, leading to its acquisition by Allergan in 2003. He served as a co-founder, Director and Chairman of the SAB of Macusight, an ophthalmic pharmaceutical company developing proprietary mTor inhibitors for ophthalmic disease, which was acquired by Santen in 2010. He was a founder and director of Peak Surgical, an innovator in pulsed plasma mediated electro-surgery that was acquired by Medtronics in 2011. In 2004 he co-founded Optimedica Corporation for which he co-wrote the foundation IP for the PASCAL and Catalys lasers, and which was acquired by AMO. In 2006 he co-founded and served as Chairman of the Board of Adverum Biotechnologies (ADVM:NASDAQ) until October 2016. He was a co-founder and director of Oculeve, a dry eye company employing a neuro-modulatory approach to therapy, which was acquired by Allergan in August of 2015. He serves as a director of Kala Pharmaceuticals, BVI Visitec, One Medical, Managing Director of Lagunita Biosciences LLC and until its recent acquisition, Chairman and CEO of Kedalion Therapeutics.

Join Replay

Help us to author the future of genomic medicine